Search Results - "Arimura, Nanaka"
-
1
Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease
Published in Journal of controlled release (01-03-2023)“…Non-alcoholic fatty liver disease (NAFLD) currently affects about 25% of the world's population, and the numbers continue to rise as the number of obese…”
Get full text
Journal Article -
2
Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway
Published in Toxins (18-12-2021)“…Activation of mTORC1 (mechanistic target of rapamycin complex 1) in renal tissue has been reported in chronic kidney disease (CKD)-induced renal fibrosis…”
Get full text
Journal Article -
3
Advanced oxidation protein products contribute to chronic kidney disease‐induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathway
Published in Journal of cachexia, sarcopenia and muscle (01-12-2021)“…Background Sarcopenia with chronic kidney disease (CKD) progression is associated with life prognosis. Oxidative stress has attracted interest as a trigger for…”
Get full text
Journal Article -
4
Indoxyl Sulfate Contributes to Adipose Tissue Inflammation through the Activation of NADPH Oxidase
Published in Toxins (05-08-2020)“…Adipose tissue inflammation appears to be a risk factor for the progression of chronic kidney disease (CKD), but the effect of CKD on adipose tissue…”
Get full text
Journal Article -
5
Advanced Oxidation Protein Products Contribute to Chronic-Kidney-Disease-Induced Adipose Inflammation through Macrophage Activation
Published in Toxins (26-02-2023)“…Fat atrophy and adipose tissue inflammation can cause the pathogenesis of metabolic symptoms in chronic kidney disease (CKD). During CKD, the serum levels of…”
Get full text
Journal Article -
6
Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes
Published in Diabetes care (01-06-2021)Get full text
Journal Article